A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

PURPOSE: This was a Phase I/II trial of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737 given in combination with gemcitabine. Its objectives were to establish the safety profile, recommended Phase 2 dose (RP2D), pharmacokinetics profile, and clinical activity of SRA737. PATIENTS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Robert, Plummer, Ruth, Moreno, Victor, Carter, Louise, Roda, Desamparados, Garralda, Elena, Kristeleit, Rebecca, Sarker, Debashis, Arkenau, Tobias, Roxburgh, Patricia, Walter, Harriet S., Blagden, Sarah, Anthoney, Alan, Klencke, Barbara J., Kowalski, Mark M., Banerji, Udai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539020/
https://www.ncbi.nlm.nih.gov/pubmed/36378548
http://dx.doi.org/10.1158/1078-0432.CCR-22-2074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539020/
https://www.ncbi.nlm.nih.gov/pubmed/36378548
http://dx.doi.org/10.1158/1078-0432.CCR-22-2074

Ejemplares similares